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Abstract
Some authors have noted that in biobank research participants may be guided by what is called 
therapeutic misconception, whereby participants attribute therapeutic intent to research procedures. 
This article argues that the notion of therapeutic misconception is increasingly less justifi ed when 
evaluating biobanks. We present four examples taken from recent developments in biobanking to 
argue why the notion of therapeutic misconception is problematic in that biobanking practices are 
increasingly seeking to bridge research and treatment in diff erent ways.  In this article we explore 
examples where the boundary between research and treatment become increasingly blurred, as 
well as the contextual signifi cance of healthcare systems and their prevailing ideologies in healthcare 
management. We argue that biobanking practices are challenging the use value, as well as the 
philosophical and ethical underpinnings for the need to separate research and treatment, and thus 
the notion of therapeutic misconception in the fi rst place. We call this tension between research and 
treatment ambivalent research advancement to highlight the diffi  culties that various actors have in 
managing such shifts within the healthcare-research systems. 
Keywords: biobanks, therapeutic misconception, treatment, individual research results (IRR), incidental 
fi ndings (IF), healthcare policy. 
Article
Introduction
A number of recent commentators have noted 
that in biobank research participants may be 
guided by what is called therapeutic misconcep-
tion, whereby participants attribute therapeutic 
intent to research procedures (Zawati & Knoppers, 
2012; Forsberg et al. 2009; Appelbaum et al., 1982). 
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In participating in research, some participants 
may indeed feel that they are receiving some type 
of treatment or therapy despite the fact that they 
are given an informed consent form to read and 
sign, which has stated that this is not the case. A 
number of studies have shown how the informed 
consent procedure is problematic, especially con-
cerning biobanking studies (Skolbekken et al., 
2005; Hoeyer, 2003, 2008; Hoeyer & Hogle, 2014). 
Other studies, however, have demonstrated that 
people are motivated by participating and contrib-
uting to a common good and do not expect direct 
benefi ts for themselves – even though they would 
prefer the benefi ts (Snell et al., 2012; Pellegrini et 
al., 2014; Wallace & Kent, 2011). Furthermore, in a 
number of studies where tissue samples, as well as 
health and lifestyle information is gathered, such 
as longitudinal cohort studies, people do receive 
immediate feedback and information on their 
health. These include blood pressure, body fat lev-
els, sugar levels and other pertinent health related 
information, which is often experienced as care. 
The process of participation in itself is often seen 
as an opportunity to interact and discuss personal 
health related matters with healthcare profession-
als, which further compounds the notion that par-
ticipants are receiving health related treatment, 
as opposed to participating in research (Nobile et 
al., 2013). Some have argued that it is not a mis-
conception to assume one will receive good care 
during research, but it is a misconception if one 
believes that the purpose of the research is to 
provide treatment rather than conduct research 
(Henderson et al., 2007; National Bioethics Advi-
sory Commission, 2001). It is clear, however, that 
people’s expectations about research are not 
straightforward as is not the relationship between 
research and care.
The interest to maintain a distinction between 
research and treatment and the role of the 
research subject vs patient has been a long-
standing issue within medical ethics. The roots 
of this lie in important policy documents, such 
as the Belmont report (1979), which sought to 
protect human research subjects from unwittingly 
becoming enrolled within research projects, but 
also to ensure that research participants are able 
to make an informed decision (Halverson and 
Friedman Ross, 2012). The dichotomy between 
research and treatment has been well established 
and rigorously defended from a philosophical and 
ethical perspective, whereby the practice of main-
taining this distinction has been meant to protect 
patients from possible harms, which may come 
about through enrolling in research without being 
fully aware of the consequences.  
The debate of separation of research and 
treatment has, however, had a somewhat diff erent 
tone in relation to biobanking. Commentators 
have sought to point out how biobank research 
diff ers fundamentally from other types of clinical 
research, such as drug trials, in that it does not 
require further intervention into the human body 
(except for the drawing of blood for cohort studies, 
for example) (Deschênes et al., 2001; Hansson et 
al., 2006; Cambon-Thomsen et al., 2007). Some 
have also suggested that biobank research ought 
to be comparable to registry-based research in 
that samples drawn from patients are comparable 
to any other type of data collected on the patient 
(Aromaa et al., 2002). Such positions have sought 
to argue that biobankers can withdraw from an 
ethical debate relating to therapeutic misconcep-
tion, whereas in fact biobanking is increasingly 
collapsing research and treatment in novel ways. 
This collapse in the distinction between research 
and treatment is giving rise to novel forms of 
responsibility and ambiguity to various practi-
tioners, such as physicians, biobankers, as well as 
laboratory technicians (cf. Wadmann & Hoeyer, 
2014). Indeed, there are increasing examples 
of the diffi  culties that states, for example, have 
in trying to define the scope of responsibility 
between, patients, research subjects, physicians, 
and biobankers when it comes to managing 
fi ndings (Tupasela, 2015; Tupasela & Liede, 2016).
As such, the notion of therapeutic miscon-
ception, which is used to describe scenarios 
and situations where patients may become 
unwittingly research subjects, also falls under 
question as a useful theoretical and analytical 
tool for understanding the ways in which research 
and treatment are changing with relation to 
biobanking. As Dresser (2002: 276) has noted, 
“intentionally or inadvertently, they [researchers] 
encourage participants’ therapeutic expecta-
tions in numerous ways. Some encouragement 
comes from the consent forms that are supposed 
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to explain how research participation will diff er 
from ordinary patient care.” For new biobanking 
practices, however, the situation is further 
compounded by the very context in which the 
distinctions between research and treatment are 
becoming increasingly blurred.
This article contextualizes this discussion 
within a broader framework where it is increas-
ingly difficult to maintain a useful distinction 
between research and treatment in relation to the 
biomedical collection and use of tissue samples 
and data, or biobanking. We provide four inter-
national examples, which highlight the ways in 
which research and treatment are encroaching 
and blurring this supposed boundary as a result 
of new ways of studying disease and combining 
information gained from tissue sample collections 
and other pertinent medical information. Much 
like the artificiality of the boundary between 
basic and applied research that has been criti-
cised by Stokes (1997), we wish to suggest that 
the distinction between research and treatment 
is increasingly problematic and fails to refl ect the 
rapid changes taking place in the research and 
treatment interface. These changes are taking 
place in both the public and private sector, and 
refl ect a broader systemic shift in the way research 
and treatment are being organized in relation to 
biobanking.
The Nordic countries, in particular, have been 
able to capitalize on their ability to collect and 
compare information gained from tissues with 
registry data. Some have gone as far as to claim 
that the whole population serves as a type of 
cohort in some cases (Frank, 2000). We thus seek 
to question whether the notion of therapeutic 
misconception is useful anymore in relation to 
developments in biobanking since biobanking 
is seeking to collapse the two together. This also 
has important consequences in relation to a 
re-defi nition and redistribution of responsibili-
ties among the actors. This approach is based on 
the understanding that research fi elds, which rely 
on biobanks for example, are not just governed 
from above. Instead, we would like to suggest 
that research drawing on biobanking is also 
giving rise to novel forms of medical intervention 
and treatment where the relationship between 
treatment and research is by design iterative and 
reflexive, as opposed to distinct and separate. 
The rapid development of biobanking during the 
past decade has brought with it a number of chal-
lenges for both the medical research system, as 
well as the delivery of healthcare in general. At the 
heart of this challenge lies a progressive ideology 
regarding the way in which medical research is 
conducted, as well as the ways in which illness is 
detected and treated.  
In the following, we will seek to contextualize 
how we see developments in biobanking as prob-
lematizing the very notion of therapeutic miscon-
ception through four examples. We argue that 
rather than seeking to continuously uphold the 
dichotomy of research and treatment, one should 
begin to recognize the myriad of ways in which 
biobanking practices, as well as some policies, 
are giving rise to novel ways of treating people, 
and developing ways in which practices can be 
accounted for and recognized in legal and ethical 
discourse.  Although some of these approaches 
are problematic, we nonetheless consider it an 
important policy step to try and account for this 
change as opposed to fi ght it.
Methods and Materials
This research is based on a two-year project, 
which sought to understand the forms and styles 
of engagement that various biobanks under-
took in six countries: USA, Canada, UK, Spain, 
Finland and Iceland. Although the main remit of 
our research was to focus on engagement strate-
gies of biobanks in these diff erent countries, our 
data also produced results on the ways in which 
biobanks come about, as well as the multifac-
eted contexts in which they operate.  This broad 
variation provides a contrast to the general inter-
national policies and guidelines regarding the 
separation of research and treatment. It became 
evident during our research that a number of 
biobanking constellations were in fact blurring 
the boundary between research and treatment, 
whereby it became increasingly diffi  cult for actors 
to justify the existing dichotomy. In conducting 
our research, we did 26 interviews with relevant 
personnel from different biobanks, as well as 
biobank networks in six diff erent countries. We 
also conducted interviews with policy makers 
and regulators in the various countries to develop 
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a broader picture of the nature of biobanking in 
the various countries. Our interviews were based 
on a semi-structured interview framework where 
we focused on specifi c themes relating to sustain-
ability and engagement practices. In this article, 
we focus on examples whereby we highlight and 
problematize some of the issues that are faced in 
biobanking today in relation to maintaining a dis-
tinction between research and treatment. 
In examining our data, we came across situa-
tions in which the boundary between research 
and treatment was blurred and the usefulness 
of the notion of therapeutic misconception was 
becoming an increasingly problematic concep-
tual tool to understanding the role of the patient 
in the research system vs receiving treatment. 
Here we present four examples that are drawn 
from three countries; two from Finland, one from 
the UK and one from the USA. Although one may 
say, that these cases represent ‘special’ cases, and 
are not representative, we argue that they are 
indicative of the direction in which research, using 
biobanks, is increasingly moving in. The possibili-
ties that are becoming available to researchers in 
such new confi gurations are substantially more 
competitive and productive than conventional 
research settings. We see an increasing pressure 
for research systems to move towards constella-
tions where there is increasing iteration between 
the research and clinical settings.
Biobanks and Ambivalent 
Research Settings 
A central problem related to the therapeutic mis-
conception relates to the ways in which informa-
tion derived from biobank research is, or is not, 
communicated with research subjects, as well as 
the expectations that research subjects may have 
in relation to participation in research (Eriksson, 
2004). Miller et al. (2008) have noted that there 
has emerged a new ethical imperative whereby 
researchers are increasingly expected to com-
municate the results of their research to partici-
pants. Similarly, Smith and Aufox (2013: 7) have 
noted that “new paradigms are currently needed 
for understanding and relaying research results 
made possible by current and future genetic tech-
nologies as they evolve.” On a more general level, 
the changes taking place in the biomedical fi eld 
refl ect a broader shift in the way data is collected 
and used. As Rodriguez (2013: 2) argues, society 
is becoming increasingly “data rich and depend-
ent.” As a consequence of this proliferation and 
dependence on diff erent types of data, biobank-
ing applications and uses are having profound 
effects on the way medical research and treat-
ment is being organized and delivered.
Two aspects, in particular, have played an 
important role on the discussions related to thera-
peutic misconception; the return of incidental 
fi ndings (IF) and the return of individual research 
results (IRR). A number of recent studies have 
identifi ed inconsistencies between international 
norms and guidelines on the return of IRR and 
IF, and the practices associated with biobanking. 
The studies note that there is no international 
consensus on the ways in which information 
from biobanking research should be returned to 
individuals (Wolf, 2013; Zawati & Knoppers, 2012; 
Bledsoe et al., 2013; Forsberg et al., 2009). Many of 
these studies have called for international guide-
lines regarding the return of IRR and IF (Zawati & 
Knoppers, 2012). The ambiguities associated with 
whether or not information ought to be shared 
with research participants highlights the tenuous 
relationship that biobanking is producing in 
relation to its research population in general. As 
biobanks continue to develop into more sophis-
ticated systems for the collection and analysis 
of information, so too develops their ability to 
speak back to participants and society in general 
in relation to the health risks that individuals and 
populations may have. We call this development 
ambivalent research advancement in that increas-
ingly actors involved and surrounding biobanking 
– researchers, policy makers, ethics committees, 
etc. - inhabit an ambivalent position in relation 
to how information ought to be managed 
and disseminated. In these new constellations 
between research and treatment biobanks serve 
as intermediaries through which the traditional 
boundary between research and treatment is 
becoming increasingly blurred. Biobanks are 
hailed as important sources of material and 
data for research, but increasingly the ability 
of researchers and doctors to glean immediate 
benefit for patients and research subjects is 
Science & Technology Studies 30(1)
29
becoming clearer. In this sense, we argue that the 
advancements in research are also producing a 
type of ambivalence in that the notion of thera-
peutic misconception plays an important part 
in the research ethos, whereby researchers and 
doctors still try to maintain a boundary, albeit false 
in many cases, between research and treatment.
In part, it is understandable that research 
participants may be guided by the therapeutic 
misconception given that there appears to be a 
great degree of professional ambiguity, as well 
with regards to the ways in which genetic research 
results ought to be managed. Pullman and Hodg-
kinson (2006), for example, have argued that 
although there is increasing literature regarding 
the duty of physicians to warn at risk relatives in 
the context of genetic testing (cf. Tupasela, 2006; 
Offi  t et al., 2004), not enough has been discussed 
in relation to the management of genetic research 
results. More recently, the American College 
of Medical Genetics (2013) published a recom-
mendation on reporting on clinical exome and 
genome sequencing results of 24 conditions. The 
report was met with criticism in that some felt that 
it went too far in terms of setting a requirement for 
labs and doctors to report on incidental fi ndings. 
These examples regarding return of individual 
research results and incidental fi ndings highlight 
the ways in which participation in biobank 
research is raising a number of concerns, which 
even professional groups are unable to address in 
a clear manner since biobanks play an important 
role in practices related to genetic research. The 
patchwork of practices related to reporting has 
contributed, we would argue, to an ambiguity 
in which the delineation between research and 
clinical practice is often diffi  cult to ascertain.
Zawati & Knoppers (2012) have recently noted 
that “it is important to encourage endeavours that 
aim to provide a clear set of defi nitions related 
to the return of IRRs and IFs at the international 
level.” This, according to them, will allow for much 
needed consistency in international norms and 
will reduce ambiguity and contradictions.” (Zawati 
& Knoppers, 2012: 488) Although their approach is 
commendable, we believe that it misses a crucial 
perspective related to some more recent trends in 
biobanking research and treatment, namely that 
biobanking practices and the forms of research 
that are aligned with them are giving rise to 
novel forms of intervention where the distinction 
between research and treatment is increasingly 
blurred. We argue that seeking to set standards 
and guidelines before we know and see the ways 
in which biobanking can change the ways in 
which research is done and healthcare delivered 
might lead to more problems than what is actually 
solved. A number of examples can be drawn on 
where the iterative process between research and 
treatment is becoming increasingly intermingled.
There is also a problem with the notion of ther-
apeutic misconception in relation to the develop-
ment and philosophical assumptions enshrined 
within new personalized medical technologies 
(European Commission, 2013), as well as health 
care technology management systems. This is 
because much of new personalized medicine 
being developed is founded on the idea, to some 
extent, of an ongoing iteration between the 
patient and the research where biobanks play 
a critical role (Yuille et al., 2008; Riegman et al., 
2008; EU workshop, 2003; OECD, 2001). In this 
sense, the separation of research and treatment is 
being brought together as a means of overcoming 
methodological and data problems in biomedical 
research. In order to develop more accurate data 
on and for the patient or patient populations, 
the patient and the research population need to 
be brought in closer within the ’fold’ of research 
practices. 
Furthermore, with the rise of personalized 
medicine as a major policy program for most 
Western countries there is an increased interest in 
the acceleration of the translation of knowledge 
gained from biomedical research into treatment. 
Biobanks are seen as a critical element in this 
process in that they will provide the basis from 
which actionable biomarkers can be identifi ed 
for selecting the right drug targets, as well as 
the development of new drugs in the fi rst place 
(Hewitt, 2011). Some commentators have noted 
that biobanking needs to focus increasingly 
on being evidence based and geared towards 
customer satisfaction in order to ensure long-term 
sustainability (Simeon-Dubach and Watson, 2014). 
Together these factors are infl uencing the ways in 
which research and treatment are confi gured, and 
subsequently to the development of therapeutic 
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misconceptions among biobanking research 
subjects.
In the following we will discuss four examples 
which derive from policy and legal changes, as 
well as practice-based contexts, which provide 
concrete instances where the distinction between 
research and clinical care are becoming increas-
ingly blurred. We believe that these examples 
are indicative of an increased tension between 
research and treatment involving biobanks. From 
these arguments, we seek to criticize the useful-
ness of therapeutic misconception as a useful 
category through which to critique biobanking 
practices. We argue that biobanking is increas-
ingly transcending the boundary, which has been 
enshrined within medical research ethics.
The Finnish Biobank Act
Our fi rst example regarding the blurring distinc-
tion between research and treatment comes 
from a recent development in Finland regarding 
biobanking. Finland is a small Nordic country that 
has a long tradition of registry-based research, 
as well as collecting tissue samples for research 
(Tupasela, 2004). The Nordic countries have in 
general collected and maintained numerous reg-
istries and collections related to human health 
that can be cross-referenced using a unifi ed social 
security number system In this sense, the Nordic 
countries maintain somewhat of a unique position 
internationally with regard to their collections. A 
number of these countries have also been early 
movers in terms of setting up major biobanking 
initiatives within their borders. The Norwegian 
HUNT Biobank, for example, has a collection of 
over 250 000 DNA samples, whose physical man-
agement and analysis is highly automated (HUNT 
Biobank, 2015). 
In a similar vein, Finland has also been seeking 
to develop and bolster its use of exiting tissue 
sample collections and related registry and health 
information. In doing so, it has implemented 
a new Biobank Act, which according to Soini 
(2013) is the only one of its kind in the world. 
The Act brings under one legal instrument all 
biobanks, including clinical, research, public or 
private. Besides its broad scope, the novelty of 
the Biobank Act lies in its position regarding the 
right of participants to gain access and informa-
tion regarding their samples, which appears to 
go against international trends regarding return 
of IRR (Tupasela, 2015). Burke et al. (2014: 107) 
have, for example, argued that “the weight of 
bioethical and researcher opinion argues against 
granting research subjects an unrestricted right to 
demand return of individual research results.” In 
Finland, however, the broadening of the ability of 
researchers to access samples and health related 
data has been met with increased responsibility 
to provide information on actionable fi ndings if a 
participant requests it.
Against this backdrop, it is rather surprising 
that in its Biobank Act (688/2012), the Finnish 
legislature went against the international norms 
and guidelines by including the following section 
in the Act:
A registered individual has the right to receive, 
upon request, information concerning his or 
her health as determined based on a sample. 
When providing information determined based 
on the sample, the person must be provided 
with an opportunity to receive an account of 
the signifi cance of the information. A fee may 
be charged for clarifying the signifi cance of the 
information that, at maximum, corresponds to the 
expenses incurred by providing the clarifi cation. 
(Biobank Act 688/2012 Section 39.)
From a practical perspective, this would mean 
that if a person were to know that a sample from 
them has been collected, then they would have 
a right to know if that samples has been used in 
research, as well as what types of research it has 
been used in.  Furthermore, they would also have 
the right to know – at their own expense – what 
the signifi cance of the research fi ndings have in 
relation to their own sample. This position has 
been further clarifi ed to mean that biobanks need 
only report on signifi cant and actionable results if 
any are found in the studies.  This is the fi rst time 
in which, at a national level, biobanks have been 
required to provide people whose samples have 
been used with an explanation of the signifi cance 
of the existing fi ndings in relation to their sample 
if it is actionable. This move fundamentally alters 
the nature of research and the dynamic of partici-
pation in that with the new Act, research partici-
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pants can expect that they have a legal right to 
request information if it is actionable.
This requirement, however, is not without its 
problems. As one administrator noted, the law 
raises a number of problems in relation to the 
operation of biobanks and the delivery of health-
care in society:
You can think of it by imagining that the younger, 
healthier and more active you are, then the more 
information they can get during their life from 
that biobank. They can go to the biobank and get 
all the information that they want, they can ask. 
These possibilities have been made available to 
them through the broad consent. But if they are 
active in getting this information then there are 
also going to be problems, if they suddenly want 
to know all their risks if the sample has been used 
for some research study and then returned back to 
the biobank. (Interview with hospital administrator, 
FI 2013.)
The interview excerpt highlights a new type of 
concern for Nordic countries in relation to equal-
ity in relation to healthcare access and informa-
tion, whereby younger generations may be more 
active in seeking information on their health 
based on samples being used in biobank research. 
Another interviewee was more critical in 
relation to the practical implications that it had for 
biobanks and the people working in them: 
But now it is in the law that people should get all of 
their results – it is a catastrophic passage! We don’t 
want to attract anyone to participate in that way, 
because it is enormously laborious to explain to 
them what there has been found. (Interview with 
biobank manager, FI 2013.)
This legislative requirement places a heavy bur-
den on the biobank to develop an infrastructure 
that would be able to manage research subject 
requests on a practical level.  To our knowledge, 
the biobanks that have been set up thus far in Fin-
land have not been faced with such a situation. 
Most participants are not aware of either the new 
law or the fact that their samples could be used for 
further research, but it is inevitable that someone 
will sometime in the future request information 
regarding the use of their sample, the research 
fi ndings, as well as a translation of the signifi cance 
of those fi ndings to themselves. 
We consider this to be the fi rst substantiation, 
at the national level, and codifi ed in law, whereby 
individuals whose samples have been stored 
in a biobank have the right to gain information 
regarding their samples and the research that has 
been done on it. This legal move can be seen as 
a major challenge to the traditional dichotomy 
between research and clinical care. Furthermore, 
it raises serious questions as to the functionality 
of the notion of therapeutic misconception since 
the law seeks to provide a loophole of types for 
research participants to request actionable health 
information based on research conducted on their 
tissue sample.
Hospital-based Biobank Research 
The second example we draw on comes from 
the changing role that hospitals are embrac-
ing in relation to the, often large, clinical tis-
sue sample collections, as well as health records 
that they maintain. During the past decade, the 
proliferation of biobanks around the world has 
been signifi cant. The range and scope of newly 
formed biobanks is also quite broad. One new 
type of biobank operation is that which is nested 
in existing hospital systems whereby either old 
diagnostic collections are re-purposed into new 
biobanking facilities, new collections are begun 
or a combination of these two models is adopted 
(Wilson et al., 2014). Some institutions have stored 
or archived tissue samples for more than 100 
years (Eisemann & Haga, 1999; Strong, 2000) and 
it is becoming an important asset, which hospitals 
can draw on for developing treatments and study-
ing disease in the population. Unlike population 
cohort studies, which capture a random sample 
of the population, large hospital systems will have 
a diff erent picture of the health and disease bur-
den of the local population, as well as a diff erent 
capacity to react to new fi ndings. In this sense, 
hospital-based biobanks inhabit a unique place in 
the healthcare-research nexus. This is particularly 
so in the Nordic countries where the hospital and 
healthcare system is largely a publically funded 
system. Although private medical treatment is 
available, most serious illnesses and demand-
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ing procedures will be taken care of in the public 
healthcare sector.
One example of the re-purposing of diag-
nostic sample collections, which we studied in 
our research is the Auria Biobank1, which became 
the fi rst clinical biobank established in Finland. 
The biobank was established by the University 
of Turku and the hospital districts of Southwest 
Finland, Satakunta, and Vaasa at the beginning of 
2014. The re-purposed biobank obtained a permit 
from the National Supervisory Authority for 
Welfare and Health (Valvira) to set up a biobank 
into which the diagnostic collections from these 
hospital collections could be transferred.  Most 
of the samples in the collection (about 80%) are 
samples from cancer patients, but the research of 
the biobank will also focus on diabetes and cardi-
ovascular diseases. 
In its implementation, however, the use of 
clinical samples and related health information 
the question related to therapeutic misconception 
becomes increasingly challenging for hospitals to 
manage since entering the hospital for diagnosis 
and treatment will also entail becoming entered 
within the hospital biobank system. Although 
patients receive an informed consent form before 
coming to the hospital in which they can choose 
whether their samples will be entered into the 
biobank, the case is indicative of the ways in which 
hospitals are increasingly embedding biobank 
research infrastructures within their healthcare 
systems. It also raises a number of challenges in 
relation to the return of IRR and IF as well. In imple-
menting the re-purposing of clinical samples, the 
hospital is also creating a research environment 
where the distance between patient samples and 
information and the patient becomes increasingly 
blurred. In a number of our interviews in Finland 
this issue was discussed. The idea is to “capture all 
incomers” which means that when patients are 
called for an elective procedure at the hospital 
they are sent the invitation along with a consent 
form so that samples can be entered into the 
biobank. Once they have consented, every time 
they come to have a procedure done or a test, an 
extra sample may be collected and entered into 
the biobank. Samples are collected or accrued 
in one of two ways: they are either collected 
through the lab, which is conducting a test on a 
patient and the lab screen also includes a request 
to have a sample collected for the biobank (this 
may include extraction of plasma or serum etc.). 
The second route into the biobank is through 
the operating room where they can get diff erent 
biopsies from patients. 
The integration of everyday hospital routines 
related to testing and medical procedures to 
include collection and storage activities is central 
to the blurring of the boundary between research 
and treatment in everyday medical practice. In 
one interview where we were discussing hospital 
biobanks and the re-use of existing clinical 
samples, a hospital administrator noted that:
…it would mean that a citizen would not know 
that they are the object of research, if we were 
only studying their medical records without their 
consent, but with a permit from the authorities. 
(…) in a way it would be more of a survey 
research - despite the object being a group of 
patients – where one would not be doing medical 
research where you would not need to physically 
interact with the patient, but rather using their 
information to study them. (Interview with hospital 
administrator, FI 2013.)
The interview highlighted the way in which the 
role of the patient vs research subject becomes 
increasingly complex in relation to the double 
role that begins to emerge.  Hospitals are trying 
to defi ne the boundaries between whether the 
information and samples they have from patients 
ought to be managed as information or sam-
ples, and whether their patients are patients or 
research subjects. We see this as an example of 
ambivalent research advancement, where insti-
tutions are seeking to re-defi ne the boundaries 
and defi nitions of what it means to be a patient 
and a research subject within the hospital system. 
Furthermore, the interview highlights the way in 
which tissue samples are conceptualized as a form 
of information to which other criteria for access – 
such as research access to survey data - could be 
applied in contrast to medical research permits, 
which usually assume some form of medical inter-
vention (such as drawing blood). In Finland, this 
approach is not new in relation to biobanks, but 
rather has been presented earlier whereby tissue 
samples have been compared to any other type 
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of survey or statistical data on populations to 
which a diff erent set of re-use criteria should be 
applied in relation to medical research (Aromaa et 
al., 2002).
Hospital managers are increasingly grappling 
with the diffi  culties and challenges of redefi ni-
tions of their patient populations and the samples 
and information that they manage, as well as the 
storage policies they ought to develop (Nørgaard-
Pedersen & Hougaard, 2007). Current policies and 
guidelines are not clear as to what the status of 
patients is with regard to their samples and data. 
As Douglas et al. (2012) have noted in relation 
to the secondary use of dried blood spots there 
is increasing pressure to find uses to existing 
collections to make them more productive. At 
the same time, there emerges an ambiguity as to 
the re-defi nition of patients as research subjects 
within the healthcare system and the ways in 
which information and samples on patients ought 
to be defi ned and managed.
UK Biobank Imaging Study
The third example regarding the difficulties of 
maintaining a distinction between research and 
clinical care and the challenge it poses to the 
notion of therapeutic misconception comes from 
the UK. The UK Biobank is a major collaborative 
undertaking, which recruited half a million par-
ticipants aged between 40-69 years from 2006 to 
2010 (Wallace, 2005). The people were recruited 
from across the country to take part in this project 
through general practitioners. One of the corner-
stones of the UK Biobank project has been that 
those people participating in the study by provid-
ing tissue samples, as well as health and lifestyle 
information, will not receive any personal research 
results or incidental fi ndings (Barbour, 2003). 
Recently, however, the UK Biobank and its asso-
ciated Ethics and Governance Council have had to 
make an exception to this rule with regard to the 
commencement of an imaging study that they are 
undertaking. The study requires a body scan (MRI) 
which measures accurately body fat and tissue 
composition, which will be analyzed in relation 
to other markers and lifestyle and health informa-
tion.  According to UK Biobank:
The imaging study will involve magnetic resonance 
imaging of the brain, heart and abdomen, low 
power X-ray imaging of bones and joints and 
ultrasound of neck arteries.  The feasibility phase 
is scheduled to start in 2014 in a dedicated UK 
Biobank imaging facility at its Coordinating Centre 
in Cheadle, near Stockport. (UK Biobank, 2014.)
The problem that has arisen with regard to the 
imaging study is that the radiologists who con-
duct the imaging will be able to make other per-
tinent diagnoses based on the scans and x-rays. 
Due to their professional ethical guidelines, how-
ever, those doctors are required to inform patients 
of any life threatening or serious conditions that 
may be identifi ed through the imaging. As a result, 
the UK Biobank has had to undertake a review of 
its policies, as well as conduct a study regarding IF 
and return of IRRs.  
UK Biobank is working with social scientists and 
health economists to gain a better understanding 
of the risks and benefi ts associated with providing 
feedback of potentially serious incidental fi ndings 
to UK Biobank participants during the imaging 
pilot study.  In some cases, these incidental fi ndings 
can have serious health implications; in others, 
the medical implications are less clear, and many 
potentially serious fi ndings may – after further 
investigation or the passage of time – turn out not 
to be of concern after all. The impact that feedback 
of information about potentially serious incidental 
fi ndings has on participants has not been well 
researched.  This work is important because there is 
currently no consensus in the research community 
on which (if any) incidental fi ndings should be 
fed back and the best methods for doing this. (UK 
Biobank, 2015.)
The need to re-asses the UK Biobank policy on IF 
as it relates to the imaging study is an example of 
the diffi  culty that some biobanks face in terms of 
maintaining the distinction between research and 
clinical care. The case of the UK Biobank imaging 
study suggests that even the most determined 
attempts to maintain this distinction may fail due 
to the innovative possibilities that biobanking 
research is allowing in relation to the combination 
of a multitude of diff erent research approaches. In 
some cases, however, these approaches introduce 
diff erent criteria of care and treatment with regard 
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to the patient population, whereby diff erent ethi-
cal and legal standards come into conflict with 
those which the biobank has sought to follow.
Given that hospitals are increasingly setting 
up biobanks as part of their routine sample and 
data collecting processes there also emerges the 
further problem of defi ning the limits of respon-
sibilities related to the responsibility of doctors 
towards their patients.  Since organisations repre-
senting medical professions, such as the World 
Medical Association (WMA) are issuing guide-
lines on biobanking, it is relevant to note that the 
blurring of the treatment and research boundary 
within the hospital setting may prove ethically 
challenging for doctors treating their patients. 
Furthermore, there is an increasing convergence 
between the ethical concerns of physicians, 
nurses, researchers and even lab technicians 
with regard to emerging biobanking practices. 
This may arise if important information becomes 
available through biobank research, but which 
the treating physicians do not communicate to 
her patient. An important question, which arises 
then is the extent of the physicians’ responsibility 
in seeking out information on the patients that 
they treat, as well as the responsibility of other 
actors in the biobanking knowledge production 
process. Limiting physician liability and responsi-
bility may become a necessary move in countries 
where disputes are settled through costly litiga-
tion processes, such as the US. 
A further problem relates to the notion that 
biobanks, in general, are able to control the ways 
in which their patient populations are studied. 
Much of the function of informed consent is to 
control and standardize the ways information 
gained from samples is managed (i.e. what infor-
mation is allowed to fl ow and not fl ow between 
the research subjects and the researcher). Yet this 
case and others like it suggest that the fl ow of 
information between various stakeholders is far 
more porous than what informed consent forms 
are able to account for (cf. Hoeyer et al., 2015).
The question of professional and ethical guide-
lines of radiologists, however, raises an even 
more important question in relation to the role 
of lab technicians and other research staff  who 
may possess highly specifi c skills and know-how 
in relation to making diagnosis based on infor-
mation derived from genetic tests and other 
genome sequence processes. Although a great 
deal of the work that takes place within labora-
tories where sequence data is being analyzed 
remains mundane, there is an increasing ability 
of lab technicians and other research staff  to look 
at data derived from a single person and identify 
a possible serious life threatening condition. 
Although these researchers and lab technicians 
may not be bound by a code of medical ethics to 
help patients when possible, some commenta-
tors have noted that there is a moral responsibility 
within the research community to work towards 
informing individuals of the likelihood of a serious 
condition (Miller et al., 2008; Fernandez et al., 
2003). As the development of whole genome and 
exome sequencing continues to improve and 
becomes less expensive, so does the accuracy of 
predicting more conditions become increasingly 
likely. The policy of UK Biobank to not provide 
any feedback to participants, however, has come 
under question in relation to this particular study 
and it remains to be seen whether future studies 
will also have to be evaluated on a case-by-case 
basis as new fi ndings and possibilities arise.
23andMe Genetic Self-testing
Our fi nal example relates to the American genet-
ics company 23andMe, which has been provid-
ing genetic self-tests that can be ordered over 
the internet. 23andMe provided consumers with 
health information on 254 diseases and condi-
tions, information on genealogy, as well as non-
disease traits (Zettler et al., 2014). The genetic tests 
that they provide are an exemplar of a growing 
field in the biomedical industry known as con-
sumer medicine (Tupasela, 2010) where compa-
nies provide analytical services to consumers on 
various aspects related to their health based on 
their genetic profi le. Recently, however, the Food 
and Drug Administration (FDA) has ordered the 
company to halt their operations regarding their 
self-test services due to the lack of clinical evi-
dence as to the validity of their claims to health 
benefi ts (Prainsack, 2014). The case of 23andMe is 
instructive in relation to the ways in which private 
companies have sought to capitalize and develop 
services which provide both medical information 
regarding one’s health (based on a genetic test), as 
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well as collect and study data that is provided by 
customers who have taken the genetic self-test. 
The service that 23andMe offered would allow 
for customers to answer a broad range of health 
and lifestyle related questions which would then 
be used to further study correlations between dis-
ease and single nucleotide polymorphisms (SNPs). 
The trouble with their method, according to the 
FDA and critics of 23andMe, was that in many of 
the cases the correlations on which they were bas-
ing their health risk assessments on lacked clinical 
validity and were thus misleading consumers.
Curnutte and Testa (2012) have argued that 
direct-to-consumer (DTC) genetic tests are indica-
tive of a conspicuous instance of co-production 
where genetic knowledge and biological citi-
zenship become articulated around the genetic 
consumer. We would further argue that what has 
made the case of 23andMe so signifi cant is not 
really the issue of whether its tests are able to 
provide clinical validity in relation to their signifi -
cance (although that is certainly an important 
concern), but more importantly the way in which 
23andMe has sought to combine genetic-self tests 
with their own research. Although 23andMe is one 
of many other companies that have off ered such 
tests to consumers (others include deCodeMe, 
Pathway Genomics or Interleukin Genetics) what 
has made 23andMe of interest in relation to our 
work is the ways in which it seeks to blur the 
boundary between research and treatment (in this 
case genetic risk profi ling). The FDA’s reasoning 
for forcing 23andMe to stop off ering its test had 
nothing to do with the model it was using to 
study people, but rather was focused on issues of 
validity. 
The model that 23andMe developed relied on 
two types of iteration between their customers 
and the samples that they had provided. First, 
as new studies became published related to 
diff erent genes that were implicated with various 
conditions and disease, 23andMe would update 
the profi les of its customers to refl ect either and 
increase or decrease in their risk profi le. Second, 
based on the information that the customer 
provided concerning their own health and lifestyle 
23andMe would conduct its own research into 
correlations between genes, environment and 
lifestyle. Again, these results would feed back into 
the risk profi le that the company would calculate 
for each customer. It is this closeness between 
a customers’ samples and the information that 
is produced and gleaned from other publically 
available studies, which has made 23andMe of 
interest in relation to the notion of therapeutic 
misconception. The model that they use seeks to 
be a combination of the two by collapsing the 
dichotomy between research and treatment (in 
this case genetic risk profi ling).
McGowan et al. (2010: 261) have noted that 
“early users approach personal genome scanning 
with both optimism for genomic research and 
scepticism about the technology’s current capa-
bilities.” This would seem to suggest that users 
are very wary of the type of service that they 
are receiving as well as the context in which it is 
being conducted.  The fusion of genetic analysis 
and research through questionnaires does not 
necessarily, therefore, need to be a problem, as 
may be suggested by the notion of therapeutic 
misconception. Although arguably the case of 
genetic-self-testing is unique compared to clinical 
research conducted in hospitals the issue of 
combining testing and research in DTC companies 
does not appear to produce misconceptions. 
Instead it serves more of a proof of concept that 
other practitioners may seek to harness in a more 
clinically valid and useful manner.
Although the risk profi ling services off ered by 
23andMe are no longer allowed by the FDA (in the 
USA), we argue that the time it took for the FDA to 
force the company to halt its services, combined 
with the model that the company developed, is a 
sign of what we have called ambivalent research 
advancement in that it challenges the existing 
and traditional ways of conducting research and it 
elicits a certain level of uncertainty from regulators 
as to the appropriate response. Furthermore, it 
signals the challenges and tensions, which policy 
makers confront when having to develop guide-
lines with such novel approaches to research.
 
Discussion
A number of recent commentators have noted 
how the distinction between research and treat-
ment in biobanking is becoming increasingly diffi  -
cult to delineate (Burke et al., 2014; Wadmann and 
Hoeyer, 2014; Smith and Aufox, 2013; Pullman and 
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Hodgkinson, 2006) and that this may in fact be 
contributing to what has been termed therapeutic 
misconception. Zawati and Knoppers (2012) have 
suggested that international norms ought to be 
set up to guide the return of individual research 
results and incidental fi ndings based on biobank 
research as one way of ameliorating some of 
these problems arising from this misconception. 
We argue, however, that attempts to set up inter-
national norms and guidelines fail to address the 
fundamental change that is going on in medical 
research. The distinction between the two cat-
egories (research and treatment) are becoming 
increasingly blurred, whereby research and treat-
ment are being reconfi gured in a myriad of diff er-
ent ways to such a degree that their regulation 
through policies might be diffi  cult, as well as futile 
during a period when development and change is 
so rapid. We have called this development ambiv-
alent research advancement in that it signals 
changes within the relationship between research 
and treatment in such a way as to elicit tensions 
between existing policies and new practices. This 
ambivalence also gives rise to new confi gurations 
and distributions of responsibility and author-
ity, which are not clear in all circumstances. Hoe-
yer (2008) has pointed out that traditionally the 
ambiguities related to biobanking have sought 
to be mitigated through the practice of informed 
consent, which he argues, is not a good medium 
through which rights, responsibilities and obli-
gations can be managed.  We would agree with 
this assertion and like to suggest that institutions 
(hospitals, insurance companies) and state organi-
sations begin to discuss whether the dichotomy 
between research and treatment within biobank-
ing is any longer a useful distinction.
A number of recent commentators have 
suggested that biobanks begin to develop new 
ways of dealing with fi ndings, which may have 
signifi cance to sample donors (Wolf et al., 2012). 
This line of thought has been derived from 
previous experiences of developing ways of 
warning at-risk relatives of a serious or life-threat-
ening condition (Offi  t et al., 2004; Tupasela, 2012). 
Although this could be arguably viewed as setting 
policies and guidelines for the return of inci-
dental fi ndings and individual research results, we 
suggest that it highlights the problematic notion 
of therapeutic misconception in the fi rst place. 
In many cases, it does not recognize suffi  ciently 
the changing relation and role played by research 
subjects and patients within new confi gurations 
of biobanks and healthcare systems. We have 
furthermore suggested that this tension between 
policies and practice can be called ambivalent 
research advancement because the roles and 
duties, which have traditionally been ascribed to 
patients and their privacy, are becoming increas-
ingly contested and problematic. This line of 
argumentation also follows on from the recogni-
tion that research subjects and patients can have 
a broad range of diff erent expectations related 
to participation in research, as well as medical 
treatment.
Following Dressers’ (2002) idea where research 
may indeed be contributing to notions of 
therapeutic misconception, we would like to 
emphasize that within recent biobanking devel-
opments the concept of therapeutic misconcep-
tion is increasingly problematic. This is due to the 
ways in which biobanking research is increasingly 
envisioned where the border between research 
and treatment is in fact blurry and deconstructed 
in many ways. We suggest, therefore, that instead 
of discussing issues of IF and IRR in relation to 
therapeutic misconception we begin to under-
stand the myriad ways in which biobanking 
practices are constructing novel relationships 
between research and treatment. Through this 
understanding we can begin to develop a new 
theoretical understanding of the changing role of 
the research subject, the patient and the research-
treatment system into which they are embedded. 
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